BioPharma Resources

Drug Trial Radar · NCT03073967

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

A Randomized, Open Label, Multi-center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir for the Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1)

Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 158 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

158

Actual

Start

May 8, 2017

Primary completion

Aug 15, 2025

Study completion Nov 11, 2025

Sponsor

Sponsor type
Industry
Collaborators
Medpace, Inc.
First posted
Mar 8, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state plasma concentration) or investigators choice, which can be either foscarnet 40 mg/kg every 8 hours or 60 mg/kg every 12 hours, or Cidofovir iv 5 mg/kg body weight given once weekly, or Cidofovir 1% or 3% topical applied 2 to 4 times daily, or Imiquimod 5% topical 3 times per week) (provided the drug is nationally approved).

Conditions

  • HSV Infection

Interventions

  • PritelivirDrug

    100 mg oral tablets

  • Investigator's choiceDrug

    Foscarnet iv, 40 mg/kg BW tid or 60mg/kg bid or Cidofovir iv, 5 mg/kg BW given once weekly or Cidofovir 1% or 3%, topically applied 2 to 4 times daily or Imiquimod 5%, Solution for iv infusion or topical application

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy measured by cure rateTime frame: Up to a maximum of 28 days

Locations

70 sites in 15 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Metro Infectious Disease Consultants, LLC - Huntsville

    Huntsville, Alabama

  • University of South Alabama

    Mobile, Alabama

  • University Arizona - Department of Medicine Arizona Health Sciences Center

    Tucson, Arizona

  • City of Hope

    Duarte, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of California, Division of Infectious Diseases

    Sacramento, California

  • Midland Florida Clinical Research Center, LLC

    DeLand, Florida

  • Midway Immunology and Research Center (MIRC)

    Ft. Pierce, Florida

  • University of Florida (UF) - Division of Infectious Disease

    Gainesville, Florida

  • Links Clinical Trials

    Miami, Florida

  • University of South Florida

    Tampa, Florida

  • Emory Hospital Midtown Infectious Disease Clinic

    Atlanta, Georgia

  • Metro Infectious Disease Consultants - Atlanta

    Decatur, Georgia

  • Metro Infectious Disease Consultants, LLC

    Burr Ridge, Illinois

  • Department of Medicine J. H. Stroger Hospital of Cook County

    Chicago, Illinois

  • LSU Health Baton Rouge Pulmonary Clinic

    Baton Rouge, Louisiana

  • Tulane University - School of Medicine

    New Orleans, Louisiana

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • University of Minnesota

    Minneapolis, Minnesota

  • Lee's Summit MO United States 64086

    Lee's Summit, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Rutgers Robert Wood Johnson Medical School

    New Brunswick, New Jersey

  • Kings Country Hospital Center

    Brooklyn, New York

  • David H. Koch Center at Memorial Sloan Kettering Cancer Center

    New York, New York

  • Duke University Medical Center - Division of Infectious Diseases

    Durham, North Carolina

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Penn State Health Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Hospital Rawson

    Córdoba, Argentina

  • Sanatorio Mayo Privado S.A.

    Córdoba, Argentina

  • Instituto FIDES

    La Plata, Argentina

  • Melbourne Health - Royal Melbourne Hospital

    Parkville, Australia

  • Westmead Hospital, Centre for Infectious Disease and Microbiology

    Westmead, Australia

  • AZ Sint-Jan Brugge

    Bruges, Belgium

  • Centre Hospitalier Universitaire Saint Pierre

    Brussels, Belgium

Showing 40 of 70 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.